[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100394964":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":31,"locations":37,"responsibleParty":241,"collaborators":24,"id":243,"slug":244,"hasResults":245,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":24,"eligibilityCriteria":249,"healthyVolunteers":245,"sex":250,"minAge":251,"maxAge":24,"enrollmentInfo":252,"targetDuration":24,"studyType":255,"phases":256,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":285},{"fullName":5,"class":6},"Cabaletta Bio","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DSG3-CAART","EXPERIMENTAL","Single or multiple intravenous infusion(s) of DSG3-CAART at varying dose levels.\n\nThis study is now closed to enrollment.",[13],"Biological: DSG3-CAART",{"label":15,"type":10,"description":16,"interventionNames":17},"CABA-201","Infusion of CABA-201 with or without cyclophosphamide and fludarabine preconditioning, or with or without cyclophosphamide preconditioning.\n\nThis sub-study is open to enrollment.",[18],"Biological: CABA-201",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Intravenous infusions of DSG3-CAART alone at different doses and different fractionations, with or without intravenous immunoglobulin, cyclophosphamide, and\u002For fludarabine.",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Single intravenous infusion of CABA-201 at escalating doses, with or without preconditioning.",[15],[29],{"name":5,"affiliation":5,"role":30},"STUDY_CHAIR",[32],{"name":5,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","+1 267 759 3100","4444","clinicaltrials@cabalettabio.com",[38,60,76,93,110,127,147,157,170,180,197,214,230],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Stanford University, Dept. of Dermatology","RECRUITING","Redwood City","California","94063","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-122.23635,37.48522,{"lat":50,"lon":49},[53,57],{"name":54,"role":33,"phone":55,"phoneExt":24,"email":56},"Kunju Sridhar, PhD","650-721-4902","kunju@stanford.edu",{"name":58,"role":59,"phone":24,"phoneExt":24,"email":24},"M. Peter Marinkovich, MD","PRINCIPAL_INVESTIGATOR",{"facility":61,"status":40,"city":62,"state":42,"zip":63,"country":44,"countryCode":45,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"UC Davis, Dept. of Dermatology","Sacramento","95816",{"type":47,"coordinates":65},[66,67],-121.4944,38.58157,{"lat":67,"lon":66},[70,74],{"name":71,"role":33,"phone":72,"phoneExt":24,"email":73},"Lauren Downing","916-551-2635","ladowning@ucdavis.edu",{"name":75,"role":59,"phone":24,"phoneExt":24,"email":24},"Mehrdad Abedi, MD",{"facility":77,"status":40,"city":78,"state":79,"zip":80,"country":44,"countryCode":45,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Yale University","New Haven","Connecticut","06520",{"type":47,"coordinates":82},[83,84],-72.92816,41.30815,{"lat":84,"lon":83},[87,91],{"name":88,"role":33,"phone":89,"phoneExt":24,"email":90},"Andrea DeClement","475-255-8031","andrea.declement@yale.edu",{"name":92,"role":59,"phone":24,"phoneExt":24,"email":24},"Mary Tomayko, MD, PhD",{"facility":94,"status":40,"city":95,"state":96,"zip":97,"country":44,"countryCode":45,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Northwestern University","Chicago","Illinois","60611",{"type":47,"coordinates":99},[100,101],-87.65005,41.85003,{"lat":101,"lon":100},[104,108],{"name":105,"role":33,"phone":106,"phoneExt":24,"email":107},"NU Dermatology CTU","312-503-5944","NUderm-research@northwestern.edu",{"name":109,"role":59,"phone":24,"phoneExt":24,"email":24},"Alan Zhou, MD",{"facility":111,"status":40,"city":112,"state":113,"zip":114,"country":44,"countryCode":45,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"University of Iowa","Iowa City","Iowa","52242",{"type":47,"coordinates":116},[117,118],-91.53017,41.66113,{"lat":118,"lon":117},[121,125],{"name":122,"role":33,"phone":123,"phoneExt":24,"email":124},"Amanda Howell","319-384-6843","amanda-steahr@uiowa.edu",{"name":126,"role":59,"phone":24,"phoneExt":24,"email":24},"Emma Killoran, MD",{"facility":128,"status":40,"city":129,"state":130,"zip":131,"country":44,"countryCode":45,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Brigham and Women's Hospital","Boston","Massachusetts","02115",{"type":47,"coordinates":133},[134,135],-71.05977,42.35843,{"lat":135,"lon":134},[138,142,145],{"name":139,"role":33,"phone":140,"phoneExt":24,"email":141},"Sydney Chase","617-525-7638","schase@bwh.harvard.edu",{"name":143,"role":33,"phone":24,"phoneExt":24,"email":144},"Rebecca Wenzel-Rideout","rwenzel-rideout@bwh.harvard.edu",{"name":146,"role":59,"phone":24,"phoneExt":24,"email":24},"Arash Mostaghimi, MD, MPH, FAAD",{"facility":148,"status":149,"city":150,"state":150,"zip":151,"country":44,"countryCode":45,"cosmosGeoPoint":152,"geoPoint":156,"contacts":24},"Mount Sinai - Icahn School of Medicine","WITHDRAWN","New York","10029",{"type":47,"coordinates":153},[154,155],-74.00597,40.71427,{"lat":155,"lon":154},{"facility":158,"status":40,"city":150,"state":150,"zip":159,"country":44,"countryCode":45,"cosmosGeoPoint":160,"geoPoint":162,"contacts":163},"Columbia University","10032",{"type":47,"coordinates":161},[154,155],{"lat":155,"lon":154},[164,168],{"name":165,"role":33,"phone":166,"phoneExt":24,"email":167},"Hei Ton \"Jason\" Chan","646-317-6360","htc2110@cumc.columbia.edu",{"name":169,"role":59,"phone":24,"phoneExt":24,"email":24},"Alexandra Coromilas, MD",{"facility":171,"status":149,"city":172,"state":173,"zip":174,"country":44,"countryCode":45,"cosmosGeoPoint":175,"geoPoint":179,"contacts":24},"University of North Carolina, Department of Dermatology","Chapel Hill","North Carolina","27516",{"type":47,"coordinates":176},[177,178],-79.05584,35.9132,{"lat":178,"lon":177},{"facility":181,"status":40,"city":182,"state":183,"zip":184,"country":44,"countryCode":45,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"University of Pennsylvania","Philadelphia","Pennsylvania","19104",{"type":47,"coordinates":186},[187,188],-75.16362,39.95238,{"lat":188,"lon":187},[191,195],{"name":192,"role":33,"phone":193,"phoneExt":24,"email":194},"Marie DeMarco","215-349-5699","marie.demarco@pennmedicine.upenn.edu",{"name":196,"role":59,"phone":24,"phoneExt":24,"email":24},"David Porter, MD",{"facility":198,"status":40,"city":199,"state":200,"zip":201,"country":44,"countryCode":45,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"UT Southwestern Medical Center, Dept. of Dermatology","Dallas","Texas","75235",{"type":47,"coordinates":203},[204,205],-96.80667,32.78306,{"lat":205,"lon":204},[208,212],{"name":209,"role":33,"phone":210,"phoneExt":24,"email":211},"Aleuna Lee","214-645-8968","aleuna.lee@utsouthwestern.edu",{"name":213,"role":59,"phone":24,"phoneExt":24,"email":24},"Arturo Dominguez, MD",{"facility":215,"status":40,"city":216,"state":200,"zip":217,"country":44,"countryCode":45,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"MD Anderson Texas Medical Center","Houston","77030",{"type":47,"coordinates":219},[220,221],-95.36327,29.76328,{"lat":221,"lon":220},[224,228],{"name":225,"role":33,"phone":226,"phoneExt":24,"email":227},"Alda Ashu","713-792-1280","abmiraso@mdanderson.org",{"name":229,"role":59,"phone":24,"phoneExt":24,"email":24},"Omar Pacha, MD",{"facility":231,"status":232,"city":233,"state":234,"zip":235,"country":44,"countryCode":45,"cosmosGeoPoint":236,"geoPoint":240,"contacts":24},"University of Washington","COMPLETED","Seattle","Washington","98109",{"type":47,"coordinates":237},[238,239],-122.33207,47.60621,{"lat":239,"lon":238},{"type":242,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100394964","phase-1-a-phase-12-open-label-safety-and-dosing-study-of-autologous-cart-cells-desmoglein-3-chimeric-autoantibody-receptor-t-cells-dsg3-caart-or-cd19-specific-chimeric-antigen-receptor-t-cells-caba-201-in-subjects-with-active-pemphigus-vulgaris-reset-pv-100394964",false,"NCT04422912","A Phase 1\u002F2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)","A Phase 1\u002F2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris","Inclusion Criteria for DSG3-CAART: Closed to enrollment\n\n* Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti- DSG3 antibody ELISA\n* mPV inadequately managed by at least one standard immunosuppressive therapies\n* Active mPV at screening\n* Anti-DSG3 antibody ELISA positive at screening\n\nInclusion Criteria for CABA-201 sub-study: Open to enrollment\n\n* Age ≥18\n* Confirmed diagnosis of PV by prior or screening biopsy and prior positive DSG3 ELISA, IIF, and\u002For DIF\n* PV inadequately managed by at least one standard immunosuppressive therapy\n* Active PV at screening\n* DSG3 ELISA positive at screening\n\nExclusion Criteria:\n\n* Active cutaneous lesions associated with PV that indicates mucocutaneous rather than mucosal-dominant disease\n* Rituximab in last 12 months unless PV symptoms have recently worsened or anti-DSG3 antibody titers have recently increased\n* Prednisone \\> 0.25mg\u002Fkg\u002Fday\n* Other autoimmune disorder requiring immunosuppressive therapies\n* Investigational treatment in last 3 months\n\nExclusion Criteria for CABA-201 sub-study\n\n* Have paraneoplastic pemphigus or active malignancy (not including non-melanoma skin cancer) or malignancy diagnosed within the previous 5 years\n* Have received rituximab or other anti-CD20 or anti-CD19 therapies in last 12 months unless anti-DSG3 antibody titers have recently increased or PV symptoms have recently worsened\n* Prednisone \\> 0.25mg\u002Fkg\u002Fday\n* Other autoimmune disorder requiring immunosuppressive therapies\n* Treatment with any investigational agent within 4 weeks or 5 half-lives, whichever is longer.","ALL","18 Years",{"count":253,"type":254},40,"ESTIMATED","INTERVENTIONAL",[257,258],"PHASE1","PHASE2","A phase 1\u002F2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \\[DSG3-CAART\\] or CD19-specific Chimeric Antigen Receptor T cells \\[CABA-201\\]) in subjects with active, pemphigus vulgaris",[261],"Pemphigus Vulgaris",[263,261,264,265,266,267,268,269,270,271,272,15,273,274,275],"Pemphigus","CAAR-T Therapy","CAR-T Therapy","Desmoglein 3","Cell Therapy","Autoimmune Disease","Autoimmunity","Skin Diseases, Vesiculobullous","Immunotherapy, Adoptive","Immune System Diseases","Anti-CD19 CAR-T therapy","Resecabtagene Autoleucel","Rese-cel","2026-05-28",{"date":278,"type":279},"2026-05-29","ACTUAL",{"date":281,"type":279},"2020-09-29",{"date":283,"type":254},"2029-01",{"name":5,"class":6},13]